Psoriatic Arthritis News

BOSTON — Rheumatologists need to do more to better understand the unique burdens and frustrations experienced by patients with multiple immune-mediated inflammatory diseases, according to Lilly Stairs, head of patient advocacy for Clara Health and a board member at the American Autoimmune Related Diseases Association.

BOSTON — The recently published results of the CANTOS trial, which demonstrated that targeting inflammation significantly improved cardiovascular mortality outcomes, could drastically impact the focus of treatment for patients with autoimmune and inflammatory diseases, according to recent presentation here.

BOSTON — Advances in the understanding of epigenetic modifications — changes in gene activity without changes in DNA sequencing — could lead to the development of new biomarkers and potential therapies for immune-modulated inflammatory diseases, according to a presentation given at the Interdisciplinary Autoimmune Summit.

BOSTON — Rheumatologists, gastroenterologists, dermatologists, immunologists and other health care providers who care for patients with immune-mediated inflammatory diseases will gather at the Interdisciplinary Autoimmune Summit in Boston this weekend for a collaborative discussion of treatment strategies.

Certolizumab pegol for chronic inflammatory disease does not pose a teratogenic risk for pregnant women, nor does it increase the risk for fetal death, according to findings published in Arthritis & Rheumatology.

Subcutaneous secukinumab in doses of 300 mg and 150 mg significantly improved symptoms of psoriatic arthritis, and slowed the disease’s radiographic progression at 24 weeks, according to findings published in Annals of the Rheumatic Diseases.

Recently published findings revealed that women with rheumatoid arthritis and psoriasis have an increased risk for major adverse cardiac events compared with the general population.

Samsung Bioepis and Abbvie have reached a global settlement agreement regarding the commercialization of SB5, the proposed adalimumab biosimilar for Humira, according to a press release.

Patients with arthritis who are younger, have rheumatoid factor positivity and demonstrate higher disease activity at baseline are at an increased risk for experiencing methotrexate failure due to inefficacy, according to findings published in Arthritis Care & Research.

Anti–TNF therapy is effective in patients with ankylosing spondylitis and psoriatic arthritis at 4 months, and becomes progressively more effective during the next 3 years, with a drug retention rate of approximately 60%, according to findings published in the Journal of Clinical Rheumatology.